Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Emerging Treatments for OA: New Therapies Target Joint Pain, Not Just Structural Damage

  |  Issue: January 2019  |  

Susan Bernstein is a freelance medical journalist based in Atlanta.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum. 2012 Jun;64(6):1697–1707.
  2. Tortorella MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins. Science. 1999 Jun 4;284(5420):1664–1666.
  3. Pratta MA, Yao W, Decicco C, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003 Nov 14;278(46):45539–45545.
  4. Werkmann D, Buyse MA, Dejager L, et al. In vitro characterization of the ADAMTS-5 specific nanobody M6495. Osteoarthritis Cartilage. 2018 Apr;26(Suppl 1):S178.
  5. Van der Aar EM, Desrivot J, Fagard L, et al. ADAMTS-5 inhibitor GLPG1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects. Osteoarthritis Cartilage. 2018 Apr;26(1):S310.
  6. Lindström E, Rizoska B, Tunblad K, et al. The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. J Transl Med. 2018 Mar 9;16(1):56.
  7. Conaghan PG, Bowes MA, Kingsbury SR, et al. Six months’ treatment with MIV-711, a novel Cathepsin K inhibitor, induces osteoarthritis structure modification: results from a randomized, double-blind, placebo-controlled Phase IIA trial. Osteoarthritis Cartilage. 2018 Apr;26(1):S25–S26.
  8. Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017 Jun;23(6):775–781.
  9. Yazici Y, McAlindon TE, Gibofsky A, et al. Results from a 52-week, randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular Wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 2018 Apr;26(1):S293–S294.
  10. Timmins KA, Leech RD, Batt ME, et al. Running and knee osteoarthritis: A systematic review and meta-analysis. Am J Sports Med. 2017 May;45(6):1447–1457.
  11. Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: A randomised controlled trial. Ann Rheum Dis. 2012 Aug;71(8):1322–1328.
  12. Sagar DR, Ashraf F, Xu L, et al. Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. Ann Rheum Dis. 2014 Aug;73(8):1558–1565.
  13. Xing RL, Zhao LR, Wang PM. Bisphosphonates therapy for osteoarthritis: A meta-analysis of randomized controlled trials. Springerplus. 2016 Oct 3;5(1):1704.
  14. Stoppiello LA, Mapp PI, Wilson D, et al. Structural associations of symptomatic knee osteoarthritis. Arthritis Rheumatol. 2014 Nov;66(11):3018–3027.
  15. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. New Engl J Med. 2010 Oct 14;363(16):1521–1531.
  16. Webb MP, Helander EM, Menard BL, et al. Tanezumab: a selective humanized mAb for chronic lower back pain. Ther Clin Risk Manag. 2018 Feb 21;14:361–367.
  17. Schnitzer TJ, Ekman EF, Spierings EL, et al. Efficacy and safety of tanezumab monotherapy or combined with nonsteroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015 Jun;74(6):1202–1211.
  18. Gigout A, Guehring H, Froemel D, et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthritis Cartilage. 2017 Nov;25(11):1858–1867.
  19. Hochberg M, Guermazi A, Guering H, et al. Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised, placebo-controlled, phase II study. Ann Rheum Dis. 2018 Jun;77(Suppl 2):80–81.
  20. Ha CW, Cho JJ, Elmallah RK, et al. A multi-center, single-blind, phase IIa clinical trial to evaluate the efficacy and safety of a cell-mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev. 2015 Jun;26(2):125–130.
  21. Guermazi A, Kalsi G, Niu J, et al. Structural effects of intra-articular TGFβ-1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial. BMC Musculoskelet Disord. 2017;18:461.
  22. Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008 Dec;67(12):1716–1723.

Related Articles